GSK at two-year low, drug firms hit on vaccine sceptic US health appointmentProactive Investors • 11/15/24
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine SalesZacks Investment Research • 10/30/24
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024Benzinga • 10/30/24
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVYPRNewsWire • 10/28/24
New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV DiseaseBusiness Wire • 10/24/24
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)Zacks Investment Research • 10/15/24